KalVista Pharmaceuticals (KALV) EBIT (QoQ) (2014 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -7.23% |
| Oct 31, 2024 | -3.61% |
| Jul 31, 2024 | 8.75% |
| Apr 30, 2024 | -46.16% |
| Jan 31, 2024 | -11.45% |
| Oct 31, 2023 | -2.24% |
| Jul 31, 2023 | 8.30% |
| Apr 30, 2023 | -17.75% |
| Jan 31, 2023 | -4.10% |
| Oct 31, 2022 | 1.65% |
| Jul 31, 2022 | 1.85% |
| Apr 30, 2022 | -0.48% |
| Jan 31, 2022 | -13.05% |
| Oct 31, 2021 | -20.94% |
| Jul 31, 2021 | -8.17% |
| Apr 30, 2021 | -42.55% |
| Jan 31, 2021 | 0.97% |
| Oct 31, 2020 | 11.51% |
| Jul 31, 2020 | -61.25% |
| Apr 30, 2020 | 29.61% |
| Jan 31, 2020 | -36.98% |
| Oct 31, 2019 | 2.88% |
| Jul 31, 2019 | 15.06% |
| Apr 30, 2019 | -69.07% |
| Jan 31, 2019 | -36.11% |
| Oct 31, 2018 | 30.19% |
| Jul 31, 2018 | -136.07% |
| Apr 30, 2018 | 31.68% |
| Jan 31, 2018 | 26.80% |
| Oct 31, 2017 | -8.88% |
| Jul 31, 2017 | -7.22% |
| Apr 30, 2017 | 37.34% |
| Jan 31, 2017 | -101.66% |
| Oct 31, 2016 | 21.39% |
| Mar 31, 2016 | -17.22% |
| Dec 31, 2015 | -13.68% |
| Sep 30, 2015 | 13.55% |
| Jun 30, 2015 | -15.63% |
| Sep 30, 2014 | -46.47% |
| Jun 30, 2014 | -31.25% |